Your browser doesn't support javascript.
loading
Effectiveness of Bio-K+ for the prevention of Clostridioides difficile infection: Stepped-wedge cluster-randomized controlled trial.
Leal, Jenine; Shen, Ye; Faris, Peter; Dalton, Bruce; Sabuda, Deana; Ocampo, Wrechelle; Bresee, Lauren; Chow, Blanda; Fletcher, Jared R; Henderson, Elizabeth; Kaufman, Jaime; Kim, Joseph; Raman, Maitreyi; Kraft, Scott; Lamont, Nicole C; Larios, Oscar; Missaghi, Bayan; Holroyd-Leduc, Jayna; Louie, Thomas; Conly, John.
Afiliación
  • Leal J; Infection Prevention and Control, Alberta Health Services, Alberta, Canada.
  • Shen Y; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Faris P; Department of Microbiology, Immunology, and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Dalton B; O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada.
  • Sabuda D; Infection Prevention and Control, Alberta Health Services, Alberta, Canada.
  • Ocampo W; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Bresee L; Department of Analytics, Alberta Health Services, Alberta, Canada.
  • Chow B; Pharmacy Services, Alberta Health Services, Calgary, Alberta, Canada.
  • Fletcher JR; Pharmacy Services, Alberta Health Services, Calgary, Alberta, Canada.
  • Henderson E; O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada.
  • Kaufman J; W21 Research and Innovation Centre, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada.
  • Kim J; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Raman M; O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada.
  • Kraft S; Infection Prevention and Control, Alberta Health Services, Alberta, Canada.
  • Lamont NC; Department of Health and Physical Education, Mount Royal University, Calgary, Alberta, Canada.
  • Larios O; Infection Prevention and Control, Alberta Health Services, Alberta, Canada.
  • Missaghi B; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Holroyd-Leduc J; Department of Microbiology, Immunology, and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Louie T; O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada.
  • Conly J; W21 Research and Innovation Centre, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada.
Infect Control Hosp Epidemiol ; 45(4): 443-451, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38073551
ABSTRACT

OBJECTIVE:

To evaluate the impact of administering probiotics to prevent Clostridioides difficile infection (CDI) among patients receiving therapeutic antibiotics.

DESIGN:

Stepped-wedge cluster-randomized trial between September 1, 2016, and August 31, 2019.

SETTING:

This study was conducted in 4 acute-care hospitals across an integrated health region. PATIENTS Hospitalized patients, aged ≥55 years.

METHODS:

Patients were given 2 probiotic capsules daily (Bio-K+, Laval, Quebec, Canada), containing 50 billion colony-forming units of Lactobacillus acidophilus CL1285, L. casei LBC80R, and L. rhamnosus CLR2. We measured hospital-acquired CDI (HA-CDI) and the number of positive C. difficile tests per 10,000 patient days as well as adherence to administration of Bio-K+ within 48 and 72 hours of antibiotic administration. Mixed-effects generalized linear models, adjusted for influenza admissions and facility characteristics, were used to evaluate the impact of the intervention on outcomes.

RESULTS:

Overall adherence of Bio-K+ administration ranged from 76.9% to 84.6% when stratified by facility and periods. Rates of adherence to administration within 48 and 72 hours of antibiotic treatment were 60.2% -71.4% and 66.7%-75.8%, respectively. In the adjusted analysis, there was no change in HA-CDI (incidence rate ratio [IRR], 0.92; 95% confidence interval [CI], 0.68-1.23) or C. difficile positivity rate (IRR, 1.05; 95% CI, 0.89-1.24). Discharged patients may not have received a complete course of Bio-K+. Our hospitals had a low baseline incidence of HA-CDI. Patients who did not receive Bio-K+ may have differential risks of acquiring CDI, introducing selection bias.

CONCLUSIONS:

Hospitals considering probiotics as a primary prevention strategy should consider the baseline incidence of HA-CDI in their population and timing of probiotics relative to the start of antimicrobial administration.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infección Hospitalaria / Clostridioides difficile / Infecciones por Clostridium / Probióticos / Antiinfecciosos Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Infect Control Hosp Epidemiol Asunto de la revista: DOENCAS TRANSMISSIVEIS / ENFERMAGEM / EPIDEMIOLOGIA / HOSPITAIS Año: 2024 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infección Hospitalaria / Clostridioides difficile / Infecciones por Clostridium / Probióticos / Antiinfecciosos Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Infect Control Hosp Epidemiol Asunto de la revista: DOENCAS TRANSMISSIVEIS / ENFERMAGEM / EPIDEMIOLOGIA / HOSPITAIS Año: 2024 Tipo del documento: Article País de afiliación: Canadá